Meta Title: “Roche Ltd Patent: System for Identifying Nucleic Acid Bases with Nanopore Technology

According to GlobalData’s company profile on F. Hoffmann-La Roche, Cancer treatment biomarkers was a key innovation area identified from patents. F. Hoffmann-La Roche‘s grant share as of January 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.

System for identifying nucleic acid bases using nanopore technology

Source: United States Patent and Trademark Office (USPTO). Credit: F. Hoffmann-La Roche Ltd

A recently granted patent (Publication Number: US11884024B2) discloses a system designed to identify the base of a nucleic acid molecule using a nanopore-based approach. The system includes a sensing circuit connected to a nanopore, an electrical circuit for applying electrical stimuli, and a processor programmed to control the circuits. The processor records electrical measurements as the nucleic acid molecule passes through the nanopore under different electrical stimuli, allowing for the identification of bases based on these measurements. By repeating the electrical measurements under similar or different conditions, the system aims to increase confidence in the identification process.

Furthermore, the system described in the patent includes features such as applying progression and reverse progression electrical stimuli with different polarities to manipulate the movement of the nucleic acid molecule through the nanopore. This method allows for the recording of electrical measurements indicative of the bases present in the molecule, aiding in the accurate identification of the base. Additionally, the system can target specific regions of the nucleic acid molecule, such as single-nucleotide polymorphism sites or protein binding sites, by adjusting the magnitude of the electrical stimuli. Overall, the system offers a comprehensive approach to base identification in nucleic acid molecules, with the potential for applications in various fields such as genomics and personalized medicine.

To know more about GlobalData’s detailed insights on F. Hoffmann-La Roche, buy the report here.

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies